BCAB

BioAtla, Inc. [BCAB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BCAB Stock Summary

Top 10 Correlated ETFs

BCAB

Top 10 Correlated Stocks

BCAB

In the News

BCAB Financial details

Company Rating
-
Market Cap
150.54M
Income
-121.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
65
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.99
Forward P/E
-
PEG
1.91
P/S
-
P/B
1.29
P/C
-
P/FCF
-1.21
Quick Ratio
3.97
Current Ratio
3.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.56
EPS next Y
-
EPS next Q
-
EPS this Y
-4.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
22.64%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-21.3%
SMA50
-54.18%
SMA100
-78.83%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-88%
ROC
-1.12%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.24-4.068
52W High
-3.5%
52W Low
+286%
RSI
47.97
Rel Volume
0.15
Avg Volume
522.21K
Volume
76.71K
Perf Week
13.53%
Perf Month
-8.31%
Perf Quarter
-90.25%
Perf Half Y
-90.02%
-
-
-
-
Beta
1.063
-
-
Volatility
0.18%, 0.44%
Prev Close
8.43%
Price
3.86
Change
9.04%

Something similar

Top by Market Cap
AMZN
TL0.DE
AVGO
FXAIX
BRK-B
Top Correlated ETFs
HAUZ
FPFD
EPRF
XIDD.L
KJ7.SI
Top Correlated Stocks
JTEKTINDIA.NS
CG
ESP
KOKUYOCMLN.NS
PUNJABCHEM.NS
Similar Market Cap
0953.HK
CBLSX
EWMC
CARB.L
CCLAX

Company Profile

Healthcare Biotechnology
  • Volume Average 522.21K
  • Market Capitalization 150.54M
  • Employee 65
  • CEO Dr. Jay M. Short Ph.D.
  • Headquarters San Diego,CA,US
  • IPO Date 2020-12-16
  • Website https://www.bioatla.com

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.